Fredag 22 November | 10:22:26 Europe / Stockholm

Kalender

Tid*
2024-12-17 - Årsstämma
2024-11-30 - Bokslutskommuniké 2024
2024-11-12 - Extra Bolagsstämma 2024
2024-08-15 - Kvartalsrapport 2024-Q3
2024-05-30 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q2
2024-03-01 - X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 - Bokslutskommuniké 2023
2024-02-14 - Kvartalsrapport 2024-Q1
2023-12-15 - X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 - Kvartalsrapport 2023-Q3
2023-05-17 - Kvartalsrapport 2023-Q2
2023-04-14 - Extra Bolagsstämma 2023
2023-02-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Årsstämma
2023-02-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 - Bokslutskommuniké 2022
2022-08-13 - Kvartalsrapport 2022-Q3
2022-05-20 - Kvartalsrapport 2022-Q2
2022-02-18 - Kvartalsrapport 2022-Q1
2021-12-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 - Årsstämma
2021-11-18 - Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2024-10-21 09:15:51

Milestone Reached: Shares Digitalized and Pre-Sale Preparation Underway

Following our previous update on September 26, 2024, we are pleased to provide an update on the latest developments regarding CANNORDIC A/S's upcoming IPO on the German Stock Exchange. As part of our preparations, 5,000,000 shares have been successfully digitalized and assigned the ISIN number: DK0063296751. VP Securities is managing this process and will initiate the shares once the CANNORDIC pre-sale begins.

Our Financial Advisor in Germany, in collaboration with our team, is finalizing the prospectus for the German market, keeping us on track for the planned IPO. The pre-sale of CANNORDIC shares will offer an exclusive opportunity for early investors to acquire shares before the IPO launch.

Upcoming Market Analysis for CS MEDICA
A draft analysis of CS MEDICA's valuation in Germany is underway and expected to be finalized next week, with public release to follow. This will provide key insights into our dual listing and growth potential in the EU market.

Next Steps:
The next step is the pre-sale of CANNORDIC shares, offering an exclusive opportunity to acquire shares before the IPO. Simultaneously, we are progressing on the details necessary to initiate the corporate action regarding the distribution of CANNORDIC shares to CS MEDICA investors, as previously announced. The exact details of this distribution will be communicated once the timeline is finalized.

We will keep you updated on key milestones.

Lone Henriksen
CEO, CS MEDICA A/S